Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 25, No 10 (April 1), 2007: pp. 1196-1208
© 2007 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2006.07.8626

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Faury, D.
Right arrow Articles by Jabado, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Faury, D.
Right arrow Articles by Jabado, N.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Molecular Profiling Identifies Prognostic Subgroups of Pediatric Glioblastoma and Shows Increased YB-1 Expression in Tumors

Damien Faury, André Nantel, Sandra E. Dunn, Marie-Christine Guiot, Takrima Haque, Péter Hauser, Miklós Garami, László Bognár, Zoltán Hanzély, Pawel P. Liberski, Enrique Lopez-Aguilar, Elvis T. Valera, Luis G. Tone, Anne-Sophie Carret, Rolando F. Del Maestro, Martin Gleave, Jose-Luis Montes, Torsten Pietsch, Stephen Albrecht, Nada Jabado

From the Division of Hemato-Oncology, Department of Pediatrics; Department of Pathology, Montréal Children's Hospital Research Institute; Division of Neuro-Surgery, Montréal Children's Hospital; Division of Neuro-Surgery and the Brain Tumor Research Center, Montréal Neurological Institute, McGill University Health Center; Biotechnology Research Institute, National Research Council of Canada, Montréal; Laboratory for Oncogenomic Research, Department of Pediatrics, British Columbia Research Institute for Children's and Women's Health; Department of Surgery, Prostate Cancer Center, Jack Bell Research Laboratories, Vancouver; Second Department of Pediatrics, Semmelweis University; Division of Neuro-surgery, Division of Pathology, National Institute of Neurosurgery, Budapest, Hungary; Department of Neuropathology, Medical University of Lodz, Lodz, Poland; Oncology Department, Pediatrics Hospital, Centro Medico Nacional Siglo XXI, Mexico City, Mexico; Department of Pediatrics, University Hospital, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, São Paulo, Brazil; Institut of Neuropathology, University of Bonn, Bonn, Germany

Address reprint requests to Nada Jabado, MD, PhD, Montreal Children's Hospital Research Institute, 4060 Ste Catherine West, PT-239, Montreal, Quebec, Canada H3Z 2Z3; e-mail: nada.jabado{at}mcgill.ca

Purpose Pediatric glioblastoma (pGBM) is a rare, but devastating brain tumor. In contrast to GBM in adults (aGBM), little is known about the mechanisms underlying its development. Our aim is to gain insight into the molecular pathways of pGBM.

Materials and Methods Thirty-two pGBM and seven aGBM samples were investigated using biochemical and transcriptional profiling. Ras and Akt pathway activation was assessed through the phosphorylation of downstream effectors, and gene expression profiles were generated using the University Health Network Human 19K cDNA arrays. Results were validated using real-time polymerase chain reaction and immunohistochemistry and compared with existing data sets on aGBM.

Results There are at least two subsets of pGBM. One subset, associated with Ras and Akt pathway activation, has very poor prognosis and exhibits increased expression of genes related to proliferation and to a neural stem-cell phenotype, similar to findings in aggressive aGBM. This subset was still molecularly distinguishable from aGBM after unsupervised and supervised analysis of expression profiles. A second subset, with better prognosis, is not associated with activation of Akt and Ras pathways, may originate from astroglial progenitors, and does not express gene signatures and markers shown to be associated with long-term survival in aGBM. Both subsets of pGBM show overexpression of Y-box-protein-1 that may help drive oncogenesis in this tumor.

Conclusion Our work, the first study of gene expression profiles in pGBM, provides valuable insight into active pathways and targets in a cancer with minimal survival, and suggests that these tumors cannot be understood exclusively through studies of aGBM.

Supported by the Canadian Institute of Health Research and the Penny Cole Foundation (N.J.), an NRC Genome Health Initiative grant (A.N.), the Hungarian Scientific Research Fund (O.T.K.A.) Contract No. T-04639, and the National Research and Development Fund (N.K.F.P.) Contract No. 1A/002/2004 (P.H., M.G., L.B., Z.H.). N.J. is the recipient of a Chercheur Boursier Award from Fonds de la Recherche en Sante du Québec.

D.F. and A.N. contributed equally to this article.

This is National Research Council publication No. 47482.

Terms in blue are defined in the glossary, found at the end of this article and online at www.jco.org.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
J Child NeurolHome page
S. Pfister, C. Hartmann, and A. Korshunov
Histology and Molecular Pathology of Pediatric Brain Tumors
J Child Neurol, November 1, 2009; 24(11): 1375 - 1386.
[Abstract] [PDF]


Home page
Neuro OncologyHome page
H.-Q. Qu, K. Jacob, S. Fatet, B. Ge, D. Barnett, O. Delattre, D. Faury, A. Montpetit, L. Solomon, P. Hauser, et al.
Genome-wide profiling using single-nucleotide polymorphism arrays identifies novel chromosomal imbalances in pediatric glioblastomas
Neuro Oncology, October 15, 2009; (2009) nop001v1.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
E. De Carli, X. Wang, S. Puget, F. Ducray, Y. Marie, M. Sanson, Z. Reitman, and H. Yan
IDH1 and IDH2 mutations in gliomas.
N. Engl. J. Med., May 21, 2009; 360(21): 2248 - 2248.
[Full Text] [PDF]


Home page
J. Nutr.Home page
D. Garcia-Crespo, E. Knock, N. Jabado, and R. Rozen
Intestinal Neoplasia Induced by Low Dietary Folate Is Associated with Altered Tumor Expression Profiles and Decreased Apoptosis in Mouse Normal Intestine
J. Nutr., March 1, 2009; 139(3): 488 - 494.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Broniscer, S. J. Baker, C. F. Stewart, T. E. Merchant, F. H. Laningham, P. Schaiquevich, M. Kocak, E. B. Morris, R. Endersby, D. W. Ellison, et al.
Phase I and Pharmacokinetic Studies of Erlotinib Administered Concurrently with Radiotherapy for Children, Adolescents, and Young Adults with High-Grade Glioma
Clin. Cancer Res., January 15, 2009; 15(2): 701 - 707.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
A. Martinez-Cardus, E. Martinez-Balibrea, E. Bandres, R. Malumbres, A. Gines, J. L. Manzano, M. Taron, J. Garcia-Foncillas, and A. Abad
Pharmacogenomic approach for the identification of novel determinants of acquired resistance to oxaliplatin in colorectal cancer
Mol. Cancer Ther., January 1, 2009; 8(1): 194 - 202.
[Abstract] [Full Text] [PDF]


Home page
J Child NeurolHome page
I. F. Pollack
Diagnostic and Therapeutic Stratification of Childhood Brain Tumors: Implications for Translational Research
J Child Neurol, October 1, 2008; 23(10): 1179 - 1185.
[Abstract] [PDF]


Home page
Cancer Res.Home page
T. Fujii, A. Kawahara, Y. Basaki, S. Hattori, K. Nakashima, K. Nakano, K. Shirouzu, K. Kohno, T. Yanagawa, H. Yamana, et al.
Expression of HER2 and Estrogen Receptor {alpha} Depends upon Nuclear Localization of Y-Box Binding Protein-1 in Human Breast Cancers
Cancer Res., March 1, 2008; 68(5): 1504 - 1512.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. Haque, D. Faury, S. Albrecht, E. Lopez-Aguilar, P. Hauser, M. Garami, Z. Hanzely, L. Bognar, R. F. Del Maestro, J. Atkinson, et al.
Gene Expression Profiling from Formalin-Fixed Paraffin-Embedded Tumors of Pediatric Glioblastoma
Clin. Cancer Res., November 1, 2007; 13(21): 6284 - 6292.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
K. To, Y. Zhao, H. Jiang, K. Hu, M. Wang, J. Wu, C. Lee, D. W. Yokom, A. L. Stratford, U. Klinge, et al.
The Phosphoinositide-Dependent Kinase-1 Inhibitor 2-Amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-acetamide (OSU-03012) Prevents Y-Box Binding Protein-1 from Inducing Epidermal Growth Factor Receptor
Mol. Pharmacol., September 1, 2007; 72(3): 641 - 652.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2007 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online